ULI Europe Life Sciences and Healthcare Product Council: The Evolution of the Life Science Industry Driving Property Requirements


Tuesday, September 22nd, 2020
2:00pm - 3:30pm

Choose Your Calendar


    Online This webinar will be hosted by Zoom. UNITED KINGDOM
    To register for the meeting please email Emily.DeSimone@uli.org
    14:00   Introduction by Council Chairs
                Ryan Matenchuk, Managing Director, Galileo Labs
                Martin Field, Development Manager, Willmott Dixon Construction Limited
    14:10   Presentations
                The evolution of the Boston life science property ecosystem
                Owen Thomas, CEO, Boston Properties
                The evolution of the drug discovery/ collaborative research model
                Alexandros Charitou, Director, Guidehouse
                The evolution of government support for the industry
                Pete Wilder, Head of Property, Oxford Sciences Innovation
    14:40   Key Questions Following the Presentation
    1) How have these shifts changed the nature of the life science property market?
    2) Are these trends continuing or changing?
    3) Industry shifts - How has tech changed the life science industry?
    4) How does investments like the Francis Crick Institute influence these trends?
    5) Where is the industry going? Newer trends after Covid?
    15:15   Next Steps: Product Council Membership and Governance 
    To register for the meeting please email Emily.DeSimone@uli.org



    Alexandros Charitou

    Director, Guidehouse

    Alexandros Charitou is a director in Life Sciences and the European MedTech practice leader. With more than 20 years of experience in healthcare and life sciences, he provides expertise in strategic commercial opportunity assessments, clinical advisory, and regulatory strategy supporting both medical technology and pharmaceutical companies. Alexandros is a subject matter expert on the new European Medical Device Regulations as well as European medical device regulatory and commercial strategy. He has a special interest in drug-device combination products and medical software. He works closely with start-ups, medical device and pharmaceutical clients helping them with: • Medical Technology and Pharmaceutical Due Diligence, Commercial Strategy and Brand Planning • Clinical evidence and quality systems for CE marking of SaMDs, digital and connected health products • European Medical Device Regulatory Affairs, MDR Transition and implementation • CE Marking, Clinical Evaluation, Risk Assessment ISO 14971, NHS Safety Case to DCB 0129 • ISO 13485 Quality Management System design, implementation, remediation and auditing • Application of agile methodologies in medical device manufacturing Alexandros studied medicine at the Royal Free Hospital in London and followed on with higher surgical training in cardiothoracic and major trauma surgery. He was a cardiothoracic surgeon in the UK and clinical lead for chest trauma, responsible for developing and running the chest trauma service at one of London's major trauma centres.


    Owen Thomas

    Chief Executive Officer, Boston Properties

    Owen D. Thomas is the Chief Executive Officer and a Director of Boston Properties. He is a Director of Lehman Brothers Holdings and served as its first Chairman from 2012 until 2013 when he joined Boston Properties. Prior to Lehman, Mr. Thomas was with Morgan Stanley for 24 years serving in a number of different roles, business units and locations, including Chief Executive Officer of Morgan Stanley Asia and Chairman of Mitsubishi UFJ Morgan Stanley Securities, while living in Hong Kong from 2008 until 2011. He also held the roles of President of Morgan Stanley Investment Management, Head of Morgan Stanley Real Estate and served on Morgan Stanley's Management Committee from 2005 until 2011. Mr. Thomas is the Global Chairman of the Urban Land Institute, a Director of the Urban Land Institute Foundation, a Director of the Real Estate Roundtable, and a member of the Executive Board of the National Association of Real Estate Investment Trusts. He is a Director of Episcopal Charities of New York and formerly Chairman of the Pension Real Estate Association and Director of the University of Virginia Investment Management Company. He attended and is a former Trustee of Woodberry Forest School, received a B.S. in Mechanical Engineering from the University of Virginia and an M.B.A. from Harvard Business School.


    Peter Wilder

    Oxford Sciences

    Pete is the Head of Property, having joined OSI in July 2019. Previously he was a partner with Bidwells, a property consultancy with a focus on the science and tech sector. Prior to this he was a director at JLL, an international property consultancy where he advised Man Group, Barclays, Bloomberg, Deutsche Bank and GSK. Pete is responsible for managing OSI’s growing property portfolio and for providing strategic advice to OSI portfolio companies.